---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-000927"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:09:00.548268+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ

## Summary
- Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).
- Full-year 2024 revenue $48.0-48.2M, down 8% YoY; Advanced Energy down 11% to $38.5-38.7M.
- OEM revenue Q4 $2.1M (-17% YoY); full-year $9.5M (+6% YoY).
- New AYON Body Contouring System expected to launch H2 2025 pending FDA clearance.
- CEO cites doubled U.S. generator unit sales in H2 vs H1 and GLP-1-driven demand for skin treatments.

## SEC filing metadata
- accession: 0001437749-25-000927
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774925000927/0001437749-25-000927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774925000927/apyx20250110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-000927
- JSON: https://secwatch.observer/filing/0001437749-25-000927.json
- Plain text: https://secwatch.observer/filing/0001437749-25-000927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.